Peak Processing（PKP）株式概要アルテア・グループ・ホールディングス・リミテッドは、オーストラリア、英国、カナダ、ドイツ、アイルランドで大麻ベースの医薬品および娯楽用大麻製品を製造、流通、販売している。 詳細PKP ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性2/6配当金0/6報酬過去5年間の収益は年間1.2%増加しました。 リスク分析マイナスの株主資本 過去1年間で株主の希薄化は大幅に進んだ 意味のある時価総額がありません ( A$20M )すべてのリスクチェックを見るPKP Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueAU$Current PriceAU$0.01810.0% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-19m28m2016201920222025202620282031Revenue AU$19.4mEarnings AU$2.9mAdvancedSet Fair ValueView all narrativesFeatured narrative•Pharmaceuticals & Biotech opportunityGain Therapeuticsabout 1 month ago author updated this narrativeLOFair Value from Lou_BaseneseUS$7.676.1% 割安 内在価値ディスカウントThe Market Is Sleeping on This Parkinson's Biotech - And I Think That's a MistakeGain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read full narrative4kusers have viewed this narrative23users have liked this narrative2users have commented on this narrative57users have followed this narrativeRead narrativePeak Processing Limited 競合他社Firebrick PharmaSymbol: ASX:FREMarket cap: AU$14.8mArgenica TherapeuticsSymbol: ASX:AGNMarket cap: AU$22.5mVitura HealthSymbol: ASX:VITMarket cap: AU$24.5mLittle Green PharmaSymbol: ASX:LGPMarket cap: AU$30.3m価格と性能株価の高値、安値、推移の概要Peak Processing過去の株価現在の株価AU$0.01852週高値AU$0.03752週安値AU$0.014ベータ1.331ヶ月の変化12.50%3ヶ月変化5.88%1年変化-25.00%3年間の変化-62.50%5年間の変化-95.44%IPOからの変化-96.73%最新ニュースBoard Change • May 01High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Matt Adams is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Feb 02Peak Processing Limited has completed a Follow-on Equity Offering in the amount of AUD 2.72 million.Peak Processing Limited has completed a Follow-on Equity Offering in the amount of AUD 2.72 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 150,000,000 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,000,000 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Transaction Features: Subsequent Direct Listingお知らせ • Jan 20Peak Processing Limited Announces Cessation of Employment of Brian Mbesha as CFO, Effective January 20, 2026Peak Processing Limited announced the immediate cessation of employment of its Canadian-based Chief Financial Officer (CFO), Mr. Brian Mbesha, as part of an internal restructure. This change forms part of a broader and ongoing cost optimisation program focused on strengthening financial discipline and supporting improved operational execution. Financial oversight, reporting, and controls will continue uninterrupted, led by the Company’s existing finance team, with additional interim part-time assistance from an experienced Australian-based external professional services firm accustomed to Australian reporting requirements to fulfil the CFO functions and ensure compliance and continuity during this transition period. Effective immediately on January 20, 2026.Board Change • Jan 01High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Matt Adams is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 01Althea Group Holdings Limited, Annual General Meeting, Nov 27, 2025Althea Group Holdings Limited, Annual General Meeting, Nov 27, 2025.お知らせ • Sep 17Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.55 million.Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.55 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 141,666,667 Price\Range: AUD 0.018 Discount Per Security: AUD 0.00108 Security Features: Attached Options Transaction Features: Subsequent Direct Listing最新情報をもっと見るRecent updatesBoard Change • May 01High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Matt Adams is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Feb 02Peak Processing Limited has completed a Follow-on Equity Offering in the amount of AUD 2.72 million.Peak Processing Limited has completed a Follow-on Equity Offering in the amount of AUD 2.72 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 150,000,000 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,000,000 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Transaction Features: Subsequent Direct Listingお知らせ • Jan 20Peak Processing Limited Announces Cessation of Employment of Brian Mbesha as CFO, Effective January 20, 2026Peak Processing Limited announced the immediate cessation of employment of its Canadian-based Chief Financial Officer (CFO), Mr. Brian Mbesha, as part of an internal restructure. This change forms part of a broader and ongoing cost optimisation program focused on strengthening financial discipline and supporting improved operational execution. Financial oversight, reporting, and controls will continue uninterrupted, led by the Company’s existing finance team, with additional interim part-time assistance from an experienced Australian-based external professional services firm accustomed to Australian reporting requirements to fulfil the CFO functions and ensure compliance and continuity during this transition period. Effective immediately on January 20, 2026.Board Change • Jan 01High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Matt Adams is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 01Althea Group Holdings Limited, Annual General Meeting, Nov 27, 2025Althea Group Holdings Limited, Annual General Meeting, Nov 27, 2025.お知らせ • Sep 17Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.55 million.Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.55 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 141,666,667 Price\Range: AUD 0.018 Discount Per Security: AUD 0.00108 Security Features: Attached Options Transaction Features: Subsequent Direct ListingReported Earnings • Aug 31Full year 2025 earnings released: AU$0.009 loss per share (vs AU$0.085 loss in FY 2024)Full year 2025 results: AU$0.009 loss per share (improved from AU$0.085 loss in FY 2024). Revenue: AU$15.5m (down 49% from FY 2024). Net loss: AU$4.84m (loss narrowed 85% from FY 2024). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.お知らせ • Feb 19Althea Group Holdings Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.Althea Group Holdings Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 119,000,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Name: Common Shares Security Type: Common Stock Securities Offered: 6,000,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Transaction Features: Subsequent Direct Listingお知らせ • Feb 17Althea Group Holdings Limited Appoints Matt Adams as Non-Executive DirectorAlthea Group Holdings Limited announced the appointment of Mr. Matt Adams as a Non-Executive Director, effective 17 February 2025. Mr. Adams is an experienced finance professional with over 25 years of executive-level experience across corporate finance, restructuring, and turnaround sectors. He has held senior leadership positions, including CEO, CFO, and CRO roles for both listed and unlisted entities. He is currently the Managing Director of Dynamic Corporate Investments, a boutique corporate finance firm specialising in restructuring, corporate advisory, and investment. Mr. Adams' extensive background in financial structuring, governance, and risk management will provide valuable strategic insights to AGH as the Company continues to execute its growth initiatives.お知らせ • Jan 31Althea Group Holdings Limited Announces Penelope Dobson Intention to Retire as DirectorAlthea Group Holdings Limited announced that Penelope Dobson has advised her intention to retire as director at the annual general meeting to be held on January 31, 2025.お知らせ • Dec 30Althea Group Holdings Limited, Annual General Meeting, Jan 31, 2025Althea Group Holdings Limited, Annual General Meeting, Jan 31, 2025.お知らせ • Oct 30Montu Group UK Ltd completed the acquisition of MyAccess Clinics business in the UK and Ireland of Althea Group Holdings Limited from Althea Group Holdings Limited (ASX:AGH).Montu Group UK Ltd agreed to acquire MyAccess Clinics business in the UK and Ireland of Althea Group Holdings Limited from Althea Group Holdings Limited (ASX:AGH) for AUD 1 million on October 17, 2024. The completion is subject to the following conditions precedent: Transfer of patient information; Execution of an IP Assignment Deed for the assignment of intellectual property rights o Provision and verification of data relating to patient numbers; Completion will occur 5 business days from the date on which the above conditions have been satisfied (or waived by Montu UK); and The Asset Sale Deed otherwise contains terms customary for a transaction of this nature, including in relation to representations and warranties and and is expected to complete in the coming weeks. Montu Group UK Ltd completed the acquisition of MyAccess Clinics business in the UK and Ireland of Althea Group Holdings Limited from Althea Group Holdings Limited (ASX:AGH) on October 29, 2024.Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.085 loss per share (vs AU$0.039 loss in FY 2023)Full year 2024 results: AU$0.085 loss per share (further deteriorated from AU$0.039 loss in FY 2023). Revenue: AU$30.4m (up 21% from FY 2023). Net loss: AU$32.1m (loss widened 134% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings.お知らせ • Aug 21Althea Group Holdings Limited Announces Board Changes19 August 2024: Althea Group Holdings Limited announced that Mr. Andrew Newbold will step down from his position as Non- Executive Director and Chairman of the Board on 29 August 2024, following a scheduled board meeting. Mr. Vaughan Webber will then assume the role of Chairman, effective immediately on conclusion of this meeting. Mr. Newbold has served as Non-Executive Director and Chairman since September 2018, providing exemplary leadership and guidance during a period of significant growth and transformation for AGH. The Board extend its sincere thanks to Mr. Newbold for his dedication, strategic vision, and commitment to the Company. We wish him all the best in his future endeavours. The Board announced the appointment of Mr. Vaughan Webber as the new Non-Executive Director and Chairman of Althea Group Holdings Ltd, effective immediately upon Mr. Newbold's resignation on 29 August 2024. Mr. Webber is a seasoned company director and finance executive with over 20 years of experience, possessing an in-depth understanding of ASX-listed company operations and governance. His career highlights include: Non-Executive Director, HUB24 Ltd. (2012-2018): Joined during a board restructure to help recapitalise the business, divest non-performing divisions, and support the CEO and management team in developing a robust strategy. Independent Chairman, Wentworth Holdings Ltd. (2009-2013): Oversaw the company's restructuring, the sale of its primary business operations, and the subsequent acquisition by Thorney Opportunities Ltd.お知らせ • Jul 17Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.026662 million.Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.026662 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 101,333,100 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Transaction Features: Subsequent Direct ListingNew Risk • Jul 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.2m free cash flow). Earnings have declined by 10% per year over the past 5 years. Market cap is less than US$10m (AU$11.9m market cap, or US$8.02m). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (7.6% increase in shares outstanding).New Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.2m free cash flow). Earnings have declined by 10% per year over the past 5 years. Market cap is less than US$10m (AU$11.5m market cap, or US$7.64m). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (9.7% increase in shares outstanding).お知らせ • Jan 05Althea Group Holdings Limited, Annual General Meeting, Jan 30, 2024Althea Group Holdings Limited, Annual General Meeting, Jan 30, 2024, at 17:00 AUS Eastern Standard Time. Agenda: To receive the financial statements, Directors's report and auditor's report for the Company for the financial year ended 30 June 2023; to consider the Remuneration Report; to consider the Additional 10% Placement Capacity; to consider the Re-election of Directors; to consider Short Term Incentive - Grant of Performance Rights to Joshua Fegan; to consider the Long Term Incentive - Grant of Performance Rights to Joshua Fegan; and to consider any other business that may be lawfully brought forward.New Risk • Sep 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$7.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$7.8m free cash flow). Earnings have declined by 16% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (AU$15.9m market cap, or US$10.3m).New Risk • Aug 29New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 19% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (AU$16.3m market cap, or US$10.5m).お知らせ • Jul 24Althea Group Holdings Limited Announces Approval for Althea CBD12:THC10 for Reimbursement in IrelandAlthea Group Holdings Limited announced that Ireland's Primary Care Reimbursement Service (`PCRS') has approved Althea CBD12:THC10 for reimbursement in Ireland. In a follow up to the Company's ASX announcement on 20 May 2022, Althea CBD12:THC10 has now been added to the PCRS in the Republic of Ireland, making it free of charge for Irish patients. The Rapid Review Submission for Althea CBD12:THC10 cannabis oil (50 ml), as included in Schedule 1 of the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) Regulations 2023, has resulted in the assignment of administrative codes to facilitate access to the product in line with the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) Regulations 2019 (as amended) for the specified therapeutic indications below, with an effective date of 1st August 2023: Spasticity associated with multiple sclerosis resistant to all standard therapies and interventions; Intractable nausea and vomiting associated with chemotherapy, despite the use of standard anti-emetic regimes. The agreed reimbursement price for Althea CBD12:THC10 (50ml) is 327.89, or approximately AUD 540. Multiple sclerosis (MS) is a complex inflammatory disease of the central nervous system (CNS). The onset of the disease is typically between 20 to 40 years of age, and up to 9,000 people live with this chronic condition in Ireland. Approximately 70% to 80% of adults with cancer experience chemotherapy-induced nausea and vomiting (CINV). CINV remains one of the most distressing symptoms associated with cancer therapy and is associated with decreased adherence to chemotherapy.New Risk • Jul 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 19% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (AU$16.4m market cap, or US$10.9m).お知らせ • Feb 03Althea Group Holdings Limited announced that it has received AUD 2.2 million in funding from Obsidian Global Partners, LLCAlthea Group Holdings Limited announced that it has issued unsecured convertible notes for gross proceeds of AUD 2,200,000 on February 3, 2023. The transaction included participation from institutional investor Obsidian Global Partners, LLC. The notes are convertible at a conversion price of $1.5 (AUD 2.1153) into 54,206,846 common shares of the company. The company will pay no interest on the notes. The investor may in its discretion elect to convert one or more convertible securities at the relevant conversion price by providing the company notice, provided that, where an issue of shares would result in the voting power in the company of the investor or any other person exceeding 19.99%.The notes will mature twelve months from the date which is five business days from the date of execution of the relevant agreement. The company also issued 4,800,000 options with an an exercise price equal to 200% of the 5 actual trading days immediately prior to mutual execution of the relevant agreement. The company will pay fee of 6% of the purchase price and AUD 15,000 upfront as legal cost of the transaction.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Non-Executive Director Jakob Ripshtein was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 02Full year 2022 earnings released: AU$0.04 loss per share (vs AU$0.061 loss in FY 2021)Full year 2022 results: AU$0.04 loss per share (up from AU$0.061 loss in FY 2021). Revenue: AU$20.5m (up 78% from FY 2021). Net loss: AU$12.1m (loss narrowed 19% from FY 2021). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Non-Executive Director Jakob Ripshtein was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Feb 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Non-Executive Director Jakob Ripshtein was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Breakeven Date Change • Nov 24No longer forecast to breakevenThe analyst covering Althea Group Holdings no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of AU$5.00m in 2023. New forecast suggests the company will make a loss of AU$100.0k in 2023.Reported Earnings • Sep 02Full year 2021 earnings released: AU$0.06 loss per share (vs AU$0.064 loss in FY 2020)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2021 results: Revenue: AU$11.5m (up 128% from FY 2020). Net loss: AU$15.0m (loss widened 1.9% from FY 2020).Reported Earnings • Mar 02First half 2021 earnings released: AU$0.035 loss per share (vs AU$0.037 loss in 1H 2020)The company reported a solid first half result with improved revenues and control over costs, although losses were not reduced. First half 2021 results: Revenue: AU$5.10m (up 175% from 1H 2020). Net loss: AU$8.27m (flat on 1H 2020).Is New 90 Day High Low • Feb 11New 90-day high: AU$0.57The company is up 30% from its price of AU$0.44 on 13 November 2020. The Australian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 33% over the same period.株主還元PKPAU PharmaceuticalsAU 市場7D0%-0.3%0.2%1Y-25.0%-21.3%5.8%株主還元を見る業界別リターン: PKP過去 1 年間で-21.3 % の収益を上げたAustralian Pharmaceuticals業界を下回りました。リターン対市場: PKPは、過去 1 年間で5.8 % のリターンを上げたAustralian市場を下回りました。価格変動Is PKP's price volatile compared to industry and market?PKP volatilityPKP Average Weekly Movement12.3%Pharmaceuticals Industry Average Movement11.1%Market Average Movement10.4%10% most volatile stocks in AU Market17.2%10% least volatile stocks in AU Market4.4%安定した株価: PKP 、 Australian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: PKPの 週次ボラティリティ ( 12% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2016n/aBarry Katzmanpeakprocessing.comアルテア・グループ・ホールディングス・リミテッドは、オーストラリア、英国、カナダ、ドイツ、アイルランドで大麻ベースの医薬品および娯楽用大麻製品を製造、流通、販売している。また、対象となる患者や医療専門家が薬用大麻の治療経路をナビゲートできるよう、教育、アクセス、管理サービスも提供している。さらに、飲料、エディブル、濃縮液、外用薬などの娯楽用大麻製品の処方・製造も行っており、マイ・アクセス・クリニックの名称で医療用大麻クリニックのネットワークを所有・運営している。アルテア・グループ・ホールディングス・リミテッドは2016年に設立され、オーストラリアのメルボルンに本社を置いている。もっと見るPeak Processing Limited 基礎のまとめPeak Processing の収益と売上を時価総額と比較するとどうか。PKP 基礎統計学時価総額AU$19.73m収益（TTM）-AU$10.67m売上高(TTM)AU$14.59m1.4xP/Sレシオ-1.8xPER（株価収益率PKP は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計PKP 損益計算書（TTM）収益AU$14.59m売上原価AU$7.59m売上総利益AU$7.01mその他の費用AU$17.68m収益-AU$10.67m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.0092グロス・マージン48.01%純利益率-73.16%有利子負債／自己資本比率-34.2%PKP の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/09 09:02終値2026/05/08 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Peak Processing Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関null nullPAC Partners Securities Pty. Ltd.Alexander SmithPAC Partners Securities Pty. Ltd.
Featured narrative•Pharmaceuticals & Biotech opportunityGain Therapeuticsabout 1 month ago author updated this narrativeLOFair Value from Lou_BaseneseUS$7.676.1% 割安 内在価値ディスカウントThe Market Is Sleeping on This Parkinson's Biotech - And I Think That's a MistakeGain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read full narrative4kusers have viewed this narrative23users have liked this narrative2users have commented on this narrative57users have followed this narrativeRead narrative
Board Change • May 01High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Matt Adams is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 02Peak Processing Limited has completed a Follow-on Equity Offering in the amount of AUD 2.72 million.Peak Processing Limited has completed a Follow-on Equity Offering in the amount of AUD 2.72 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 150,000,000 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,000,000 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Transaction Features: Subsequent Direct Listing
お知らせ • Jan 20Peak Processing Limited Announces Cessation of Employment of Brian Mbesha as CFO, Effective January 20, 2026Peak Processing Limited announced the immediate cessation of employment of its Canadian-based Chief Financial Officer (CFO), Mr. Brian Mbesha, as part of an internal restructure. This change forms part of a broader and ongoing cost optimisation program focused on strengthening financial discipline and supporting improved operational execution. Financial oversight, reporting, and controls will continue uninterrupted, led by the Company’s existing finance team, with additional interim part-time assistance from an experienced Australian-based external professional services firm accustomed to Australian reporting requirements to fulfil the CFO functions and ensure compliance and continuity during this transition period. Effective immediately on January 20, 2026.
Board Change • Jan 01High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Matt Adams is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 01Althea Group Holdings Limited, Annual General Meeting, Nov 27, 2025Althea Group Holdings Limited, Annual General Meeting, Nov 27, 2025.
お知らせ • Sep 17Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.55 million.Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.55 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 141,666,667 Price\Range: AUD 0.018 Discount Per Security: AUD 0.00108 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
Board Change • May 01High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Matt Adams is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 02Peak Processing Limited has completed a Follow-on Equity Offering in the amount of AUD 2.72 million.Peak Processing Limited has completed a Follow-on Equity Offering in the amount of AUD 2.72 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 150,000,000 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,000,000 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Transaction Features: Subsequent Direct Listing
お知らせ • Jan 20Peak Processing Limited Announces Cessation of Employment of Brian Mbesha as CFO, Effective January 20, 2026Peak Processing Limited announced the immediate cessation of employment of its Canadian-based Chief Financial Officer (CFO), Mr. Brian Mbesha, as part of an internal restructure. This change forms part of a broader and ongoing cost optimisation program focused on strengthening financial discipline and supporting improved operational execution. Financial oversight, reporting, and controls will continue uninterrupted, led by the Company’s existing finance team, with additional interim part-time assistance from an experienced Australian-based external professional services firm accustomed to Australian reporting requirements to fulfil the CFO functions and ensure compliance and continuity during this transition period. Effective immediately on January 20, 2026.
Board Change • Jan 01High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Matt Adams is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 01Althea Group Holdings Limited, Annual General Meeting, Nov 27, 2025Althea Group Holdings Limited, Annual General Meeting, Nov 27, 2025.
お知らせ • Sep 17Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.55 million.Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.55 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 141,666,667 Price\Range: AUD 0.018 Discount Per Security: AUD 0.00108 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.009 loss per share (vs AU$0.085 loss in FY 2024)Full year 2025 results: AU$0.009 loss per share (improved from AU$0.085 loss in FY 2024). Revenue: AU$15.5m (down 49% from FY 2024). Net loss: AU$4.84m (loss narrowed 85% from FY 2024). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.
お知らせ • Feb 19Althea Group Holdings Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.Althea Group Holdings Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 119,000,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Name: Common Shares Security Type: Common Stock Securities Offered: 6,000,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Transaction Features: Subsequent Direct Listing
お知らせ • Feb 17Althea Group Holdings Limited Appoints Matt Adams as Non-Executive DirectorAlthea Group Holdings Limited announced the appointment of Mr. Matt Adams as a Non-Executive Director, effective 17 February 2025. Mr. Adams is an experienced finance professional with over 25 years of executive-level experience across corporate finance, restructuring, and turnaround sectors. He has held senior leadership positions, including CEO, CFO, and CRO roles for both listed and unlisted entities. He is currently the Managing Director of Dynamic Corporate Investments, a boutique corporate finance firm specialising in restructuring, corporate advisory, and investment. Mr. Adams' extensive background in financial structuring, governance, and risk management will provide valuable strategic insights to AGH as the Company continues to execute its growth initiatives.
お知らせ • Jan 31Althea Group Holdings Limited Announces Penelope Dobson Intention to Retire as DirectorAlthea Group Holdings Limited announced that Penelope Dobson has advised her intention to retire as director at the annual general meeting to be held on January 31, 2025.
お知らせ • Dec 30Althea Group Holdings Limited, Annual General Meeting, Jan 31, 2025Althea Group Holdings Limited, Annual General Meeting, Jan 31, 2025.
お知らせ • Oct 30Montu Group UK Ltd completed the acquisition of MyAccess Clinics business in the UK and Ireland of Althea Group Holdings Limited from Althea Group Holdings Limited (ASX:AGH).Montu Group UK Ltd agreed to acquire MyAccess Clinics business in the UK and Ireland of Althea Group Holdings Limited from Althea Group Holdings Limited (ASX:AGH) for AUD 1 million on October 17, 2024. The completion is subject to the following conditions precedent: Transfer of patient information; Execution of an IP Assignment Deed for the assignment of intellectual property rights o Provision and verification of data relating to patient numbers; Completion will occur 5 business days from the date on which the above conditions have been satisfied (or waived by Montu UK); and The Asset Sale Deed otherwise contains terms customary for a transaction of this nature, including in relation to representations and warranties and and is expected to complete in the coming weeks. Montu Group UK Ltd completed the acquisition of MyAccess Clinics business in the UK and Ireland of Althea Group Holdings Limited from Althea Group Holdings Limited (ASX:AGH) on October 29, 2024.
Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.085 loss per share (vs AU$0.039 loss in FY 2023)Full year 2024 results: AU$0.085 loss per share (further deteriorated from AU$0.039 loss in FY 2023). Revenue: AU$30.4m (up 21% from FY 2023). Net loss: AU$32.1m (loss widened 134% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings.
お知らせ • Aug 21Althea Group Holdings Limited Announces Board Changes19 August 2024: Althea Group Holdings Limited announced that Mr. Andrew Newbold will step down from his position as Non- Executive Director and Chairman of the Board on 29 August 2024, following a scheduled board meeting. Mr. Vaughan Webber will then assume the role of Chairman, effective immediately on conclusion of this meeting. Mr. Newbold has served as Non-Executive Director and Chairman since September 2018, providing exemplary leadership and guidance during a period of significant growth and transformation for AGH. The Board extend its sincere thanks to Mr. Newbold for his dedication, strategic vision, and commitment to the Company. We wish him all the best in his future endeavours. The Board announced the appointment of Mr. Vaughan Webber as the new Non-Executive Director and Chairman of Althea Group Holdings Ltd, effective immediately upon Mr. Newbold's resignation on 29 August 2024. Mr. Webber is a seasoned company director and finance executive with over 20 years of experience, possessing an in-depth understanding of ASX-listed company operations and governance. His career highlights include: Non-Executive Director, HUB24 Ltd. (2012-2018): Joined during a board restructure to help recapitalise the business, divest non-performing divisions, and support the CEO and management team in developing a robust strategy. Independent Chairman, Wentworth Holdings Ltd. (2009-2013): Oversaw the company's restructuring, the sale of its primary business operations, and the subsequent acquisition by Thorney Opportunities Ltd.
お知らせ • Jul 17Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.026662 million.Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.026662 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 101,333,100 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Transaction Features: Subsequent Direct Listing
New Risk • Jul 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.2m free cash flow). Earnings have declined by 10% per year over the past 5 years. Market cap is less than US$10m (AU$11.9m market cap, or US$8.02m). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (7.6% increase in shares outstanding).
New Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.2m free cash flow). Earnings have declined by 10% per year over the past 5 years. Market cap is less than US$10m (AU$11.5m market cap, or US$7.64m). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (9.7% increase in shares outstanding).
お知らせ • Jan 05Althea Group Holdings Limited, Annual General Meeting, Jan 30, 2024Althea Group Holdings Limited, Annual General Meeting, Jan 30, 2024, at 17:00 AUS Eastern Standard Time. Agenda: To receive the financial statements, Directors's report and auditor's report for the Company for the financial year ended 30 June 2023; to consider the Remuneration Report; to consider the Additional 10% Placement Capacity; to consider the Re-election of Directors; to consider Short Term Incentive - Grant of Performance Rights to Joshua Fegan; to consider the Long Term Incentive - Grant of Performance Rights to Joshua Fegan; and to consider any other business that may be lawfully brought forward.
New Risk • Sep 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$7.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$7.8m free cash flow). Earnings have declined by 16% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (AU$15.9m market cap, or US$10.3m).
New Risk • Aug 29New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 19% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (AU$16.3m market cap, or US$10.5m).
お知らせ • Jul 24Althea Group Holdings Limited Announces Approval for Althea CBD12:THC10 for Reimbursement in IrelandAlthea Group Holdings Limited announced that Ireland's Primary Care Reimbursement Service (`PCRS') has approved Althea CBD12:THC10 for reimbursement in Ireland. In a follow up to the Company's ASX announcement on 20 May 2022, Althea CBD12:THC10 has now been added to the PCRS in the Republic of Ireland, making it free of charge for Irish patients. The Rapid Review Submission for Althea CBD12:THC10 cannabis oil (50 ml), as included in Schedule 1 of the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) Regulations 2023, has resulted in the assignment of administrative codes to facilitate access to the product in line with the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) Regulations 2019 (as amended) for the specified therapeutic indications below, with an effective date of 1st August 2023: Spasticity associated with multiple sclerosis resistant to all standard therapies and interventions; Intractable nausea and vomiting associated with chemotherapy, despite the use of standard anti-emetic regimes. The agreed reimbursement price for Althea CBD12:THC10 (50ml) is 327.89, or approximately AUD 540. Multiple sclerosis (MS) is a complex inflammatory disease of the central nervous system (CNS). The onset of the disease is typically between 20 to 40 years of age, and up to 9,000 people live with this chronic condition in Ireland. Approximately 70% to 80% of adults with cancer experience chemotherapy-induced nausea and vomiting (CINV). CINV remains one of the most distressing symptoms associated with cancer therapy and is associated with decreased adherence to chemotherapy.
New Risk • Jul 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 19% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (AU$16.4m market cap, or US$10.9m).
お知らせ • Feb 03Althea Group Holdings Limited announced that it has received AUD 2.2 million in funding from Obsidian Global Partners, LLCAlthea Group Holdings Limited announced that it has issued unsecured convertible notes for gross proceeds of AUD 2,200,000 on February 3, 2023. The transaction included participation from institutional investor Obsidian Global Partners, LLC. The notes are convertible at a conversion price of $1.5 (AUD 2.1153) into 54,206,846 common shares of the company. The company will pay no interest on the notes. The investor may in its discretion elect to convert one or more convertible securities at the relevant conversion price by providing the company notice, provided that, where an issue of shares would result in the voting power in the company of the investor or any other person exceeding 19.99%.The notes will mature twelve months from the date which is five business days from the date of execution of the relevant agreement. The company also issued 4,800,000 options with an an exercise price equal to 200% of the 5 actual trading days immediately prior to mutual execution of the relevant agreement. The company will pay fee of 6% of the purchase price and AUD 15,000 upfront as legal cost of the transaction.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Non-Executive Director Jakob Ripshtein was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 02Full year 2022 earnings released: AU$0.04 loss per share (vs AU$0.061 loss in FY 2021)Full year 2022 results: AU$0.04 loss per share (up from AU$0.061 loss in FY 2021). Revenue: AU$20.5m (up 78% from FY 2021). Net loss: AU$12.1m (loss narrowed 19% from FY 2021). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Non-Executive Director Jakob Ripshtein was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Feb 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Non-Executive Director Jakob Ripshtein was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Breakeven Date Change • Nov 24No longer forecast to breakevenThe analyst covering Althea Group Holdings no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of AU$5.00m in 2023. New forecast suggests the company will make a loss of AU$100.0k in 2023.
Reported Earnings • Sep 02Full year 2021 earnings released: AU$0.06 loss per share (vs AU$0.064 loss in FY 2020)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2021 results: Revenue: AU$11.5m (up 128% from FY 2020). Net loss: AU$15.0m (loss widened 1.9% from FY 2020).
Reported Earnings • Mar 02First half 2021 earnings released: AU$0.035 loss per share (vs AU$0.037 loss in 1H 2020)The company reported a solid first half result with improved revenues and control over costs, although losses were not reduced. First half 2021 results: Revenue: AU$5.10m (up 175% from 1H 2020). Net loss: AU$8.27m (flat on 1H 2020).
Is New 90 Day High Low • Feb 11New 90-day high: AU$0.57The company is up 30% from its price of AU$0.44 on 13 November 2020. The Australian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 33% over the same period.
